Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.

Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein LC, El-Naggar A, Badoual C, Fridman WH, White JM, Hadden JW.

Cancer Immunol Immunother. 2012 Jun;61(6):771-82. doi: 10.1007/s00262-011-1134-z. Epub 2011 Nov 6.

PMID:
22057678
2.

Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.

Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW.

Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):345-51.

PMID:
10722007
3.

Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.

Meneses A, Verastegui E, Barrera JL, de la Garza J, Hadden JW.

Int Immunopharmacol. 2003 Aug;3(8):1083-91.

PMID:
12860165
4.

A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.

Whiteside TL, Butterfield LH, Naylor PH, Egan JE, Hadden JW, Baltzer L, Wolf GT, Berinstein NL.

Cancer Immunol Immunother. 2012 Jun;61(6):783-8. doi: 10.1007/s00262-011-1136-x. Epub 2011 Nov 23.

5.

A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck.

Hadden J, Verastegui E, Barrera JL, Kurman M, Meneses A, Zinser JW, de la Garza J, Hadden E.

Int Immunopharmacol. 2003 Aug;3(8):1073-81.

PMID:
12860164
6.

A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.

Verastegui E, Barrera JL, Zinser J, Del Rio R, Meneses A, De La Garza J, Hadden JW.

Int J Immunopharmacol. 1997 Nov-Dec;19(11-12):619-27.

PMID:
9669202
7.

Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.

Tímár J, Ladányi A, Forster-Horváth C, Lukits J, Döme B, Remenár E, Godény M, Kásler M, Bencsik B, Répássy G, Szabó G, Velich N, Suba Z, Elo J, Balatoni Z, Pócza K, Zemplén B, Chretien P, Talor E.

J Clin Oncol. 2005 May 20;23(15):3421-32.

8.

Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery.

Meneses A, Verastegui E, Barrera JL, Zinser J, de la Garza J, Hadden JW.

Arch Pathol Lab Med. 1998 May;122(5):447-54.

PMID:
9593347
9.

Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.

Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E.

Clin Cancer Res. 2006 Jan 15;12(2):465-72.

10.

Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis.

Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD.

Otolaryngol Head Neck Surg. 1986 Sep;95(2):142-52.

PMID:
2954014
11.

Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.

Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, Snyderman C, Johnson JT, Myers E, Herberman RB, et al.

Cancer Res. 1993 Dec 1;53(23):5654-62.

12.

Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.

Junker N, Andersen MH, Wenandy L, Dombernowsky SL, Kiss K, Sørensen CH, Therkildsen MH, Von Buchwald C, Andersen E, Straten PT, Svane IM.

Cytotherapy. 2011 Aug;13(7):822-34. doi: 10.3109/14653249.2011.563291. Epub 2011 Mar 24.

PMID:
21428850
13.

Histologic and immunohistochemical characterization of tumor and inflammatory infiltrates in oral squamous cell carcinomas treated with local multikine immunotherapy: the macrophage at the front line.

Feinmesser M, Okon E, Schwartz A, Kaganovsky E, Hardy B, Aminov E, Nageris B, Sulkes J, Feinmesser R.

Eur Arch Otorhinolaryngol. 2004 Aug;261(7):359-68. Epub 2003 Oct 24.

PMID:
14576946
14.
15.

Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A.

Cancer. 2008 Sep 15;113(6):1387-95. doi: 10.1002/cncr.23712.

16.

Peri- and intratumoral T and B lymphocytic infiltration in breast cancer.

Menegaz RA, Michelin MA, Etchebehere RM, Fernandes PC, Murta EF.

Eur J Gynaecol Oncol. 2008;29(4):321-6.

PMID:
18714562
17.

A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma.

Dueñas-Gonzalez A, Verastegui E, Lopez-Graniel C, Gonzalez A, Mota A, Barrera-Franco JL, Meneses A, Chanona J, de la Garza J, Chavez-Blanco A, Hadden JW.

Int Immunopharmacol. 2002 Jun;2(7):1007-16.

PMID:
12188025
18.

Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.

Wolf GT, Fee WE Jr, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR, Gillespie MB, Freeman SM, Baltzer L, Kirkley TD, Brandwein HJ, Hadden JW.

Head Neck. 2011 Dec;33(12):1666-74. doi: 10.1002/hed.21660. Epub 2011 Jan 31.

19.

A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.

Freeman SM, Franco JL, Kenady DE, Baltzer L, Roth Z, Brandwein HJ, Hadden JW.

Am J Clin Oncol. 2011 Apr;34(2):173-8. doi: 10.1097/COC.0b013e3181dbb9d8.

PMID:
20539208
20.
Items per page

Supplemental Content

Write to the Help Desk